FLT-PET Imaging for MDS
The main purpose of this study is to see if this tracer can be used to determine how well chemotherapy is working in patients with certain types of leukemia.
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||A Pilot Study for Using 18F-FLT PET Imaging To Assess Response In Patients With Myelodysplastic Syndrome (MDS) Being Treated With 5-azacitidine|
- feasibility of using FLT-PET to assess chemotherapy response in AML/MDS [ Time Frame: 3 years ] [ Designated as safety issue: No ]This pilot study is intended to investigate the feasibility of FLT-PET for early assessment of treatment response in myelodysplastic syndrome and the use of a PET isotope, (18)F-FLT, in the imaging of bone marrow in subjects with MDS. The objectives will help gather initial information for a future, larger, more definitive study.
|Study Start Date:||July 2012|
|Estimated Primary Completion Date:||January 2015 (Final data collection date for primary outcome measure)|
Experimental: F-FLT PET scan, 5-azacitidine treatment
F-FLT Pet scan followed by 5-azacitidine treatment followed by FLT-PET scan. Three additional cycles of 5-azacytidine and follow up FLT-PET scan.
Procedure: FLT-PET scans
FLT-PET scans prior to treatment, after Cycle 1, after Cycle 4
To evaluate if FLT-PET uptake shows variation during the treatment course in subjects with MDS being treated with 5-azacitidine therapy
- To assess FLT-PET uptake heterogeneity within given subjects being treated with 5-azacitidine therapy
- To generate preliminary data regarding correlation between FLT-PET imaging parameters and clinical responses based on bone marrow aspirate/biopsy
|Contact: Ryan J Mattison, MDemail@example.com|
|Contact: Erica A Barnstablefirstname.lastname@example.org|
|United States, Wisconsin|
|University of Wisconsin||Recruiting|
|Madison, Wisconsin, United States, 53792|
|Contact: Ryan J Mattison, M.D. 608-262-5697 email@example.com|
|Principal Investigator:||Ryan J Mattison, MD||University of Wisconsin, Madison|